Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000
Key Points
Chief Medical Officer Harold Bernstein sold 9,705 shares for ~$255,000 on September 4, 2026.
The transaction involved shares equal to 100% of the insider's directly held common stock before the filing.
The sale occurred as the company's shares lost about half their value in recent months.
- 10 stocks we like better than Maze Therapeutics ›
Harold Bernstein, President of Research and Development and Chief Medical Officer at Maze Therapeutics, Inc. (NASDAQ:MAZE), sold 9,705 shares of common stock on September 4, 2026, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | ~$255,000 |
| Shares sold (directly held) | 9,705 |
| Post-transaction shares (directly held) | 0 |
| Post-transaction value | N/A |
Transaction value based on SEC Form 4 weighted average sale price ($26.22).
Key questions
- What was the nature of this transaction?
The sale was a routine execution under a Rule 10b5-1 trading plan. This arrangement allows insiders to set up a pre-determined schedule for selling stock to manage personal liquidity and portfolio diversification. - How does this sale affect Bernstein's ownership stake?
Following the transaction, the insider holds zero shares of common stock directly. The reported ownership percentage after the completion of this 9,705-share disposition stands at zero. - What is the recent performance context for Maze Therapeutics?
The stock was priced at $26.21 at the September 4, 2026 market close, down from a 52-week high of $53.65 reached in March of 2026. The transaction was executed at a weighted average price of $26.22 per share. - What are the primary clinical programs for the company?
Maze Therapeutics is a clinical stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases. Its lead programs include MZE829, which is in a phase II clinical trial for APOL1 kidney disease, and MZE782 for the treatment of phenylketonuria.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-09-10) | $24.82 |
| Market Capitalization | $1.50 billion |
| Revenue (TTM) | $20.0 million |
| Net Income (TTM) | -$133.6 million |
Company Snapshot
- Maze Therapeutics develops small molecule precision medicines targeting kidney and metabolic diseases, with lead programs including MZE829, an oral APOL1 inhibitor in Phase II clinical trials for APOL1 kidney disease, and MZE782, an oral small molecule inhibitor in Phase II-ready development for phenylketonuria treatment.
- The company operates as a clinical-stage biopharmaceutical enterprise generating revenue through research collaborations and development agreements while advancing its proprietary drug candidates through clinical development stages.
- Maze Therapeutics targets patients with rare genetic kidney and metabolic disorders, focusing on underserved patient populations with limited therapeutic options and significant unmet medical needs.
Maze Therapeutics is a clinical-stage biopharmaceutical company with a market cap of $1.50 billion, investing substantially in clinical development. The company's strategy centers on leveraging precision medicine approaches to develop targeted therapies for genetically defined kidney and metabolic diseases, positioning itself to address significant therapeutic gaps in rare disease treatment.
What this transaction means for investors
Chief Medical Officer Harold Bernstein's Sept. 4 sale of Maze Therapeutics stock resulted in the total liquidation of his direct holdings. This action is considered a non-discretionary transaction, since it was executed as part of a pre-established Rule 10b5-1 plan adopted on Sept. 29 of 2025.
Even so, the disposition at a weighted average price of $26.22 per share does not instill investor confidence in Maze Therapeutics stock, especially after shares crumbled about 50% from their 52-week high of $53.65 in March. Shares fell after Maze Therapeutics announced an offering of 5.5 million shares for $23.50 per share in April.
Bernstein's liquidation only adds to concerns about the company's future. However, a separate filing shows he owns derivative securities in the form of 160,662 stock options and 20,000 restricted stock units as of Sept. 1. This indicates he maintains a sizable equity stake in the company, ensuring his continued alignment with shareholder interests.
Should you buy stock in Maze Therapeutics right now?
Before you buy stock in Maze Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Maze Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $409,917!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,341,724!*
Now, it’s worth noting Stock Advisor’s total average return is 942% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of September 11, 2026.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
